Botensilimab

• CAT Number: I042153
• CAS Number: 2408310-37-0
• Purity: ≥95%

Botensilimab (Cat No.: I042153)  is an investigational immune checkpoint inhibitor targeting CTLA-4, engineered with enhanced Fc-effector functions to improve anti-tumor immune responses. It is designed to activate both adaptive and innate immunity by promoting T cell priming and modifying the tumor microenvironment. Botensilimab has shown promising results in early clinical trials for solid tumors, including colorectal and melanoma, particularly in patients resistant to prior immunotherapies. Its optimized design offers a novel approach to improving efficacy while reducing immune-related toxicity.

Reference

[1]. Delepine C, et, al. 470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors FREE.